{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-054504","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2023-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.349755+00:00","generated_at":"2026-06-09T16:36:32.913745+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alkermes reports Phase 1 data for ALKS 2680 showing significant sleep latency improvement in narcolepsy type 1","bullets":["ALKS 2680 demonstrated dose-dependent improvement in sleep latency: +18, +30, +37 minutes vs placebo (-1 min) at 1, 3, 8 mg (p<0.01 to p<0.001).","At 8 mg dose, patients maintained wakefulness for full 40-minute MWT up to 10 hours post-dose.","ALKS 2680 generally well tolerated; mild AEs at 8 mg (insomnia, pollakiuria, salivary hypersecretion); no serious AEs.","PK profile supports once-daily oral dosing; Phase 2 study planned for H1 2024.","First cohort (4 NT1 patients) data presented at World Sleep Congress; study also enrolling NT2 and IH patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-054504","json":"https://secwatch.observer/filing/0000950170-23-054504.json","markdown":"https://secwatch.observer/filing/0000950170-23-054504.md","text":"https://secwatch.observer/filing/0000950170-23-054504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023054504/0000950170-23-054504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023054504/alks-20231023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T16:36:32.913745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}